Physician profile
Suzanne E Campbell
NPI 1043262975
$2,775.67
in general payments reported to CMS, 2019-2025
15 companies · $475 in 2025
The $475 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $736 · 2022: $371 · 2023: $818 · 2024: $376 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,668.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,668.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $853.84 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $420.65 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $263.99 | 2022-2025 | |
| Astellas Pharma US INC | $212.70 | 2021-2023 | Veozah |
| Janssen Pharmaceuticals, INC | $197.72 | 2021-2022 | |
| Pfizer INC. | $174.51 | 2022-2025 | |
| Lilly USA, LLC | $143.36 | 2021-2025 | Jardiance, Mounjaro |
| Atricure, INC. | $135.60 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2024 | Camzyos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.39 | 2023-2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.29 | 2021-2024 | Jardiance |
| Novo Nordisk INC | $30.68 | 2023-2024 | Rybelsus, Ozempic |
| Alnylam Pharmaceuticals INC. | $22.36 | 2023 | Givlaari |
| Otsuka America Pharmaceutical, INC. | $17.82 | 2023 | Rexulti |
| Novartis Pharmaceuticals Corporation | $12.76 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.